BiotechTube
Home/Lineage Cell Therapeutics/George A. Samuel III
GA

George A. Samuel III

General Counsel & Corporate Secretary

Lineage Cell Therapeutics

Therapeutic Areas

NeurologyOphthalmologyOncology

Lineage Cell Therapeutics Pipeline

DrugIndicationPhase
OPC1Acute Spinal Cord InjuryPhase 1/2a
OpRegenGeographic Atrophy secondary to Age-related Macular DegenerationPhase 1/2a
ANP1Sensorineural Hearing LossPreclinical
VAC2Non-small Cell Lung CancerPhase 1

Leadership Team at Lineage Cell Therapeutics

BC
Brian Culley
Chief Executive Officer
JH
Jill Howe
Chief Financial Officer
DK
Derek Kelaita
Vice President of Business Development
JB
Jennifer Bahr-Davidson, Ph.D.
Vice President of Technical Operations
CH
Charlotte Hubbert, Ph.D.
Vice President, Corporate Strategy and Development
RS
Rami Skaliter, M.Sc., Ph.D.
Chief Executive Officer, Cell Cure Neurosciences
MH
Michael H. Mulroy
Chairman of the Board
DA
Dipti Amin, MBBS
Director
View full Lineage Cell Therapeutics profile